References

IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition

10.1016/s0140-6736(05)67402-8 · 2005 · External reference

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries

10.1161/circulationaha.106.676379 · 2007 · External reference

The prevalence of the metabolic syndrome in patients with schizoaffective disorder–bipolar subtype

10.1111/j.1399-5618.2004.00126.x · 2004 · External reference

Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder

10.4088/jcp.v66n0208 · 2005 · External reference

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

10.1038/oby.2003.102 · 2003 · External reference

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

10.1001/jama.2009.726 · 2009 · External reference

A placebo-controlled, random-assignment parallel group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type

10.1111/j.1399-5618.2007.00506.x · 2007 · External reference

Long term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case series

10.1016/s0924-9338(01)00562-4 · 2001 · External reference

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation

10.1097/jcp.0b013e31814b98e5 · 2007 · External reference

The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease

10.1111/j.1559-4564.2007.07392.x · 2007 · External reference

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

10.1001/jama.285.19.2486 · 2001 · External reference

Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians

10.1111/j.1399-5618.2005.00234.x · 2005 · External reference

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

10.1001/jama.287.3.356 · 2002 · External reference

Behavioral therapy for weight loss in patients with schizophrenia

2007 · External reference

American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

10.1161/circulationaha.105.169404 · 2005 · External reference

South Asians and cardiovascular risk: what clinicians should know

10.1161/circulationaha.105.583815 · 2006 · External reference

Weight decline in patients switching from olanzapine to quetiapine

10.1016/j.schres.2003.09.016 · 2004 · External reference

Unresolved reference

1976 · External reference

Metabolic syndrome in patients with schizophrenia

10.4088/jcp.v64n0513 · 2003 · External reference

The positive and negative syndrome scale (PANSS) for schizophrenia

10.1093/schbul/13.2.261 · 1987 · External reference

Obesity and medical illness in psychiatric patients admitted to a long-term psychiatric facility

10.1097/00131746-200111000-00011 · 2001 · External reference

Topiramate ameliorates hyperglycemia and improves glucose-stimulated insulin release in ZdF rats and db/db mice

10.1111/j.1463-1326.2004.00403.x · 2004 · External reference

A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders

10.1111/j.1399-5618.2007.00488.x · 2007 · External reference

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

10.1016/j.schres.2005.07.014 · 2005 · External reference

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

10.1016/j.clinthera.2005.12.005 · 2005 · External reference

10.1016/j.jdiacomp.2009.01.003

10.1016/j.jdiacomp.2009.01.003 · External reference

Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone

10.1016/j.pnpbp.2006.10.002 · 2007 · External reference

Epidemiology of metabolic syndrome in Asia

2008 · External reference

Topiramate as an adjunctive treatment in psychiatric patients with diabetes

2005 · External reference

Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the Metabolic syndrome to Asians?

10.2337/diacare.27.5.1182 · 2004 · External reference

Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension

10.1016/j.amjcard.2005.03.053 · 2005 · External reference

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study

10.1038/sj.ijo.0803382 · 2007 · External reference

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

2004 · External reference

Unresolved reference

External reference

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

10.1038/sj.ijo.0802783 · 2004 · External reference

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

10.1001/jama.2007.56-b · 2008 · External reference